# Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care

> **NCT04780516** · — · ACTIVE_NOT_RECRUITING · sponsor: **AbbVie** · enrollment: 141 (actual)

## Conditions studied

- Psoriasis

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04780516
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-04-26
- **Primary completion:** 2024-01-02
- **Final completion:** 2026-12
- **Target enrollment:** 141 (ACTUAL)
- **Last updated:** 2025-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04780516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04780516, "Study to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Psoriasis Treated With Subcutaneous Risankizumab Injection According to Standard of Care". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04780516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*